<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: One third of cases of upper-extremity <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo> (DVT) are primary, ie, they occur in the absence of central venous catheters or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Risk factors for primary upper-extremity DVT are not well established, and the recurrence rate is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: We studied 115 primary upper-extremity DVT patients and 797 healthy controls for the presence of <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> due to factor V Leiden, prothrombin G20210A, antithrombin, protein C, <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">protein S deficiency</z:e>, and <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Transient risk factors for venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> were recorded </plain></SENT>
<SENT sid="4" pm="."><plain>Recurrent upper-extremity DVT was evaluated prospectively over a median of 5.1 years of follow-up </plain></SENT>
<SENT sid="5" pm="."><plain>The adjusted odds ratio for upper-extremity DVT was 6.2 (95% CI 2.5 to 15.7) for factor V Leiden, 5.0 (95% CI 2.0 to 12.2) for prothrombin G20210A, and 4.9 (95% CI 1.1 to 22.0) for the <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> <z:e sem="disease" ids="C0033626" disease_type="Disease or Syndrome" abbrv="">protein deficiencies</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">Hyperhomocysteinemia</z:e> and oral contraceptives were not associated with upper-extremity DVT </plain></SENT>
<SENT sid="7" pm="."><plain>However, in women with factor V Leiden or prothrombin G20210A who were taking oral contraceptives, the odds ratio for upper-extremity DVT was increased up to 13.6 (95% CI 2.7 to 67.3) </plain></SENT>
<SENT sid="8" pm="."><plain>The recurrence rate was 4.4% patient-years in patients with <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> and 1.6% patient-years in those without <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>The hazard ratio for recurrent upper-extremity DVT in patients with <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> compared with those without was 2.7 (95% CI 0.7 to 9.8) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Inherited <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> is associated with an increased risk of upper-extremity DVT </plain></SENT>
<SENT sid="11" pm="."><plain>Oral contraceptives increase the risk only when combined with inherited <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>The recurrence rate of primary upper-extremity DVT is low but tends to be higher in patients with <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> than in those without </plain></SENT>
</text></document>